Search results
Insider Sale: Director James Young Sells Shares of Novavax Inc (
Guru Focus· 4 days agoOn June 18, 2024, James Young, Director at Novavax Inc (NVAX, Financial), executed a sale of 7,500 shares of the company. The transaction was filed on the same day through ...
Novavax’s South African Phase IIb COVID-19 vaccine trial likely to reveal results within next...
Pharmaceutical Technology via Yahoo Finance· 4 days agoSouth Africa’s existing regulatory, consent and ethics frameworks around HIV vaccine trial investigations helped with regards to quick initiation and straightforward progress ...
Novavax (NASDAQ:NVAX) PT Raised to $18.00
ETF DAILY NEWS· 7 days agoNovavax (NASDAQ:NVAX – Get Free Report) had its target price increased by Bank of America from $12.00 to $18.00 in a research report issued to clients and investors on Friday ...
COVID-19 is surging. Time to mask up or get a booster? What a Boise medical expert says
Idaho Statesman McClatchy via AOL· 1 day agoThe Centers for Disease Control and Prevention recommends everyone 6 months and older get an updated...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Novavax applies for FDA nod for its updated COVID vaccine
Center for Infectious Disease Research and Policy· 5 days agoThe company said it will have the vaccine ready to distribute in mid July as prefilled syringes, pending approval and recommendations.
Jim Cramer Says He's 'Going To Have To Wait' On SoFi, But Recommends This 'Great Little Industrial...
Benzinga· 5 days agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer said he still can't recommend Twilio TWLO. On June...
Why 93% Of This Biotech's Value Just Went Up In Smoke
Investor's Business Daily· 5 days agoWedbush analyst Laura Chico slashed her price target on Aerovate stock to 3 from 41, calling the...
We Won't Solve Long COVID Until We Decide What It Is
Medscape· 4 days agoIs a slow recovery from COVID-19 the lingering effects of a bad infection or the start of a new syndrome?
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...